Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.80 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | ESR1 | P03372 | 2/20 | 0.64 |
| ▸ | AHR | P35869 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | F3 | P13726 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425801 | 1.00 | MAOB (0.80) | MAOBABCG2MAPTNPC1RAB9A | |
| SCHEMBL1425782 | 0.89 | ABCG2 (0.74) | MAOBABCG2MAPTNPC1RAB9A | |
| SCHEMBL1425780 | 0.89 | ABCG2 (0.74) | MAOBABCG2MAPTNPC1RAB9A | |
| SCHEMBL1425221 | 0.89 | ABCG2 (0.74) | MAOBABCG2MAPTNPC1RAB9A | |
| SCHEMBL1425218 | 0.89 | ABCG2 (0.74) | MAOBABCG2MAPTNPC1RAB9A | |
| SCHEMBL6319119 | 0.89 | MAOB (1.00) | MAOBABCG2MAPTNPC1RAB9A | |
| SCHEMBL9818320 | 0.89 | MAOB (1.00) | MAOBABCG2MAPTNPC1RAB9A | |
| SCHEMBL9818322 | 0.89 | MAOB (1.00) | MAOBABCG2MAPTNPC1RAB9A | |
| SCHEMBL6319118 | 0.89 | MAOB (1.00) | MAOBABCG2MAPTNPC1RAB9A | |
| SCHEMBL996618 | 0.88 | ABCG2 (0.93) | MAOBABCG2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432669-B1 | 4-(C2-6 ALKOXY)-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | SPEAR THERAPEUTICS LTD (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-7112698-B2 | 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents | SPEAR THERAPEUTICS LIMITED (GB) | 2006-09-26 | — | — | US | disclosed |
| US-20040259957-A1 | 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents | SPEAR THERAPEUTICS LIMITED (GB) | 2004-12-23 | — | — | US | disclosed |
| EP-1432669-A1 | 4-(C2-6 ALKOXY)-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003029176-A1 | 4-(C2-6ALKOXY)-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259957-A1 | 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents | OXER1, ALK, BCL6 | MAOB 653/4885ABCG2 191/4885MAPT 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.